GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (NAS:PSTV) » Definitions » Effective Interest Rate on Debt %

Plus Therapeutics (Plus Therapeutics) Effective Interest Rate on Debt % : 3.42% (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Plus Therapeutics Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Plus Therapeutics's annualized positive value of Interest Expense for the quarter that ended in Mar. 2024 was $0.14 Mil. Plus Therapeutics's average total debt for the quarter that ended in Mar. 2024 was $3.97 Mil. Therefore, Plus Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 was 3.42%.


Plus Therapeutics Effective Interest Rate on Debt % Historical Data

The historical data trend for Plus Therapeutics's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plus Therapeutics Effective Interest Rate on Debt % Chart

Plus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.17 11.67 13.32 11.25 8.04

Plus Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.77 8.71 7.30 5.66 3.42

Competitive Comparison of Plus Therapeutics's Effective Interest Rate on Debt %

For the Biotechnology subindustry, Plus Therapeutics's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Plus Therapeutics's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Plus Therapeutics's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where Plus Therapeutics's Effective Interest Rate on Debt % falls into.



Plus Therapeutics Effective Interest Rate on Debt % Calculation

Plus Therapeutics's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Dec. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Dec. 2022 )+Total Debt  (A: Dec. 2023 ))/ count )
=-1  *  -0.395/( (5.645+4.181)/ 2 )
=-1  *  -0.395/4.913
=8.04 %

where

Total Debt  (A: Dec. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=3.927 + 1.718
=5.645

Total Debt  (A: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.085 + 4.096
=4.181

Plus Therapeutics's annualized Effective Interest Rate on Debt % for the quarter that ended in Mar. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Dec. 2023 )+Total Debt  (Q: Mar. 2024 ))/ count )
=-1  *  -0.136/( (4.181+3.764)/ 2 )
=-1  *  -0.136/3.9725
=3.42 %

where

Total Debt  (Q: Dec. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.085 + 4.096
=4.181

Total Debt  (Q: Mar. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=0.059 + 3.705
=3.764

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Mar. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


Plus Therapeutics  (NAS:PSTV) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


Plus Therapeutics Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of Plus Therapeutics's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


Plus Therapeutics (Plus Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
4200 Marathon Boulevard, Suite 200, Austin, TX, USA, 78756
Plus Therapeutics Inc is a clinical-stage pharmaceutical company. The company focused on the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its product pipeline includes Patented RNL and Patented DocePLUS.
Executives
Marc H Hedrick officer: President C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Robert P Lenk director LUNA INNOVATIONS INCORPORATED, 2851 COMMERCE STREET, BLACKSBURG VA 24060
Howard Clowes director 217 DWIGHT ROAD, BURLINGAME CA 94010
Greg Petersen director 3100 MAIN STREET, SUITE 900, HOUSTON TX 77002
Sims Andrew John Hugh Macintyre officer: Chief Financial Officer 4200 MARATHON BOULEVARD, SUITE 200, AUSTIN TX 78756
Norman D. Lafrance officer: CHIEF MEDICAL OFFICER MOLECULAR INSIGHT PHARMCEUTICALS, INC., 160 SECOND STREET, CAMBRIDGE MA 02142
Es-johansson An Van director 6863 BEE CAVE ROAD, SUITE 200, AUSTIN TX 78736
Ag Postfinance 10 percent owner MINGERSTRASSE 20, BERN V8 3030
Bank Sa Swissquote 10 percent owner CHEMIN DE LA CRETAUX 33, GLAND V8 1196
Anthony Gregg Lapointe director PO BOX 83216, GAITHERSBURG MD 20883-3216
Ron Martell director PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Mark Marino officer: Chief Medical Officer C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
John David Harris officer: VP and GM of Cell Therapy 3020 CALLAN ROAD, SAN DIEGO CA 92121
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
David Rickey director